ACADIA Pharmaceuticals Sponsors National Parkinson Foundation’s Caregiver Summit
September 19 2016 - 9:00AM
Business Wire
ACADIA to Host Booths and Present Posters at
the 4th World Parkinson Congress
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system (CNS) disorders, is sponsoring the National
Parkinson Foundation’s (NPF) Caregiver Summit that will be held
today in Portland, Oregon. The Caregiver Summit is a daylong event
that brings together caregivers from all over the world to share
their experiences and everyday strategies for caring for someone
with Parkinson’s disease. The Caregiver Summit immediately precedes
the 4th World Parkinson Congress, which takes place September
20-23.
“ACADIA is proud to partner with the National Parkinson
Foundation in providing caregivers with support, education and
access to much-needed resources,” said Steve Davis, ACADIA’s
President and Chief Executive Officer. “Caregivers play a vital
role in caring for people with Parkinson’s disease – but all too
often, their own needs are overlooked. The Caregiver Summit is an
important step in better understanding and addressing caregiver
needs, and we are gratified to offer our support.”
“At the National Parkinson Foundation, we understand that
Parkinson’s disease has a significant impact on people who’ve
gotten that diagnosis, as well as on those who care for and about
them,” said Vaughn Edelson, NPF’s Director of Education. “The
Caregiver Summit is an opportunity for us to offer resources and
support to caregivers now and in the future, and we look forward to
continued engagement with this important part of the Parkinson’s
community.”
ACADIA at 4th World Parkinson Congress
Following the Caregiver Summit, ACADIA will be exhibiting with
two booths at the World Parkinson Congress: Booth 700 for
healthcare providers and Booth 612, a disease education booth for
consumers. In addition, ACADIA will present three scientific
posters at the Congress:
- Decreased burden among caregivers of
patients with Parkinson’s disease psychosis (PDP) treated with
pimavanserin, a selective 5-HT2A inverse agonist (Poster
P12.08).
- Caregivers of PDP patients have an
increased risk of developing emotional and social distress that is
decreased when PDP is treated with pimavanserin (Poster
P42.11).
- The safety profile of pimavanserin:
Focus on motor symptoms and extrapyramidal-related adverse events
in patients with Parkinson’s disease psychosis (PDP) (Poster
P35.10).
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA maintains
a website at www.acadia-pharm.com to which we regularly post
copies of our press releases as well as additional information and
through which interested parties can subscribe to receive e-mail
alerts.
About the National Parkinson Foundation, a division of the
Parkinson’s Foundation
The Parkinson’s Foundation is working toward a world without
Parkinson’s disease. Formed by the merger of National Parkinson
Foundation (NPF) and the Parkinson’s Disease Foundation (PDF) in
August 2016, the mission of the Parkinson’s Foundation is to invest
in promising scientific research that will end Parkinson’s disease
and improve the lives of people with Parkinson’s, and their
families, through improved treatments, support and the best care.
For more information, visit www.parkinson.org or www.pdf.org, or
call (800) 4PD-INFO (473-4636) or (800) 457-6676.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160919005267/en/
Investor Contact:ACADIA Pharmaceuticals Inc.Lisa Barthelemy,
Investor Relations(858) 558-2871ir@acadia-pharm.comorMedia
Contact:Taft and PartnersTed Deutsch(609)
578-8765ted@taftandpartners.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Sep 2023 to Sep 2024